Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered Transcriptome Signature in Primary Human Myotubes Exposed to Inclusion Body Myositis Serum: A Pilot Case Comparison of Anti-cN1A Positive and Negative Sera.

Muscles (Basel, Switzerland)·2025
Same author

Expression and Site-Specific Biotinylation of Human Cytosolic 5'-Nucleotidase 1A in <i>Escherichia coli</i>.

Methods and protocols·2025
Same author

Balancing Clinical Applicability and Scientific Depth in ML Models for MDA5-DM Prognosis.

Briefings in bioinformatics·2024
Same author

Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models.

Clinical & translational immunology·2024
Same author

From data to diagnosis: how machine learning is revolutionizing biomarker discovery in idiopathic inflammatory myopathies.

Briefings in bioinformatics·2024
Same author

High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1*03:01:01 and highlights pathogenic role of arginine-74 of DRβ1 chain.

Journal of autoimmunity·2023
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
Same journal

Functional movement disorders: diagnosis, pathophysiology, and treatment.

Current opinion in neurology·2026
Same journal

Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities: Erratum.

Current opinion in neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Iatrogenic myopathies.

Frank L Mastaglia1

  • 1Centre for Neuromuscular and Neurological Disorders, Australian Neuromuscular Research Institute, University of Western Australia, Australia. flmast@cyllene.uwa.edu.au

Current Opinion in Neurology
|June 29, 2010
PubMed
Summary
This summary is machine-generated.

This review details statin-associated myopathies, exploring their mechanisms, genetic factors, and management. Further research is needed to clarify the true incidence and diagnostic criteria for these drug-induced muscle disorders.

Related Experiment Videos

Last Updated: Jun 11, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Area of Science:

  • Pharmacology
  • Neurology
  • Genetics

Background:

  • Therapeutic agents can induce myopathies, leading to iatrogenic muscle disorders.
  • Statin-associated myopathies are a significant clinical concern.

Purpose of the Study:

  • To review recent advancements in understanding drug-induced myopathies.
  • To focus on statin-associated myopathies, their mechanisms, and management.
  • To highlight progress in iatrogenic muscle disorder research.

Main Methods:

  • Review of recent observational and prospective studies.
  • Analysis of genetic factors influencing statin myopathy susceptibility.
  • Examination of pathogenetic mechanisms and clinical management strategies.

Main Results:

  • Statin-associated myalgia and myopathy frequency data are available, with varying myotoxicity among statins.
  • Genetic variants (SLCO1B1, CYP, COQ2) influence individual susceptibility.
  • Statins can trigger immune-mediated myopathies and exacerbate existing neuromuscular conditions.

Conclusions:

  • Recent findings expand the understanding of statin-induced myopathies and neuromuscular disorders.
  • Genetic predisposition, myotoxicity mechanisms, and management strategies are better elucidated.
  • Further prospective studies with clear diagnostic criteria are necessary to determine true incidence.